Alemtuzumab in refractory Sézary syndrome
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , |
Tipo de documento: | Relatório |
Idioma: | eng |
Título da fonte: | Anais brasileiros de dermatologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000500642 |
Resumo: | Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up. |
id |
SBD-1_6a2a96414107470d632a38a8adfddeec |
---|---|
oai_identifier_str |
oai:scielo:S0365-05962016000500642 |
network_acronym_str |
SBD-1 |
network_name_str |
Anais brasileiros de dermatologia (Online) |
repository_id_str |
|
spelling |
Alemtuzumab in refractory Sézary syndromeAntibodies, monoclonal, humanizedLymphoma, T-Cell, cutaneousSézary syndromeTreatment outcomeAbstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.Sociedade Brasileira de Dermatologia2016-10-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000500642Anais Brasileiros de Dermatologia v.91 n.5 2016reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1590/abd1806-4841.20164322info:eu-repo/semantics/openAccessReifs,Carmen María AlcántaraSalido-Vallejo,RafaelGarnacho-Saucedo,Gloria MaríaCorte-Sánchez,Sofía De laGonzález-Menchen,AlbertoGarcía-Nieto,Antonio Vélezeng2016-11-04T00:00:00Zoai:scielo:S0365-05962016000500642Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2016-11-04T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false |
dc.title.none.fl_str_mv |
Alemtuzumab in refractory Sézary syndrome |
title |
Alemtuzumab in refractory Sézary syndrome |
spellingShingle |
Alemtuzumab in refractory Sézary syndrome Reifs,Carmen María Alcántara Antibodies, monoclonal, humanized Lymphoma, T-Cell, cutaneous Sézary syndrome Treatment outcome |
title_short |
Alemtuzumab in refractory Sézary syndrome |
title_full |
Alemtuzumab in refractory Sézary syndrome |
title_fullStr |
Alemtuzumab in refractory Sézary syndrome |
title_full_unstemmed |
Alemtuzumab in refractory Sézary syndrome |
title_sort |
Alemtuzumab in refractory Sézary syndrome |
author |
Reifs,Carmen María Alcántara |
author_facet |
Reifs,Carmen María Alcántara Salido-Vallejo,Rafael Garnacho-Saucedo,Gloria María Corte-Sánchez,Sofía De la González-Menchen,Alberto García-Nieto,Antonio Vélez |
author_role |
author |
author2 |
Salido-Vallejo,Rafael Garnacho-Saucedo,Gloria María Corte-Sánchez,Sofía De la González-Menchen,Alberto García-Nieto,Antonio Vélez |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Reifs,Carmen María Alcántara Salido-Vallejo,Rafael Garnacho-Saucedo,Gloria María Corte-Sánchez,Sofía De la González-Menchen,Alberto García-Nieto,Antonio Vélez |
dc.subject.por.fl_str_mv |
Antibodies, monoclonal, humanized Lymphoma, T-Cell, cutaneous Sézary syndrome Treatment outcome |
topic |
Antibodies, monoclonal, humanized Lymphoma, T-Cell, cutaneous Sézary syndrome Treatment outcome |
description |
Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/report |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
report |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000500642 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000500642 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/abd1806-4841.20164322 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Dermatologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Dermatologia |
dc.source.none.fl_str_mv |
Anais Brasileiros de Dermatologia v.91 n.5 2016 reponame:Anais brasileiros de dermatologia (Online) instname:Sociedade Brasileira de Dermatologia (SBD) instacron:SBD |
instname_str |
Sociedade Brasileira de Dermatologia (SBD) |
instacron_str |
SBD |
institution |
SBD |
reponame_str |
Anais brasileiros de dermatologia (Online) |
collection |
Anais brasileiros de dermatologia (Online) |
repository.name.fl_str_mv |
Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD) |
repository.mail.fl_str_mv |
abd@sbd.org.br||revista@sbd.org.br |
_version_ |
1752126421382201344 |